[go: up one dir, main page]

WO1999002545A3 - Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers - Google Patents

Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers Download PDF

Info

Publication number
WO1999002545A3
WO1999002545A3 PCT/IB1998/001046 IB9801046W WO9902545A3 WO 1999002545 A3 WO1999002545 A3 WO 1999002545A3 IB 9801046 W IB9801046 W IB 9801046W WO 9902545 A3 WO9902545 A3 WO 9902545A3
Authority
WO
WIPO (PCT)
Prior art keywords
fragments
antigen binding
binding fragments
prophylaxis
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1998/001046
Other languages
French (fr)
Other versions
WO1999002545A2 (en
Inventor
Michael D Dan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viventia Bio Inc
Original Assignee
Novopharm Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novopharm Biotech Inc filed Critical Novopharm Biotech Inc
Priority to NZ501990A priority Critical patent/NZ501990A/en
Priority to EP98929569A priority patent/EP1000082A2/en
Priority to JP2000502064A priority patent/JP2001509369A/en
Priority to AU79273/98A priority patent/AU7927398A/en
Priority to CA002295375A priority patent/CA2295375A1/en
Publication of WO1999002545A2 publication Critical patent/WO1999002545A2/en
Publication of WO1999002545A3 publication Critical patent/WO1999002545A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to monoclonal antibody 4B5 and antigen binding fragments that specifically bind to the antibodies specific for GD2. Also disclosed are polynucleotide and polypeptide derivatives based on 4B5, including single chain V region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the 4B5 antibody is effective in diagnosing, and/or treating neoplasias. The invention further provides methods for treating a neoplastic disease, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and lung carcinomas. Patients who are in remission as a result of traditional modes of cancer therapy can be treated with a composition of this invention in hopes of reducing the risk of recurrence. Patients can also be treated concurrently with the antibodies and traditional anti-neoplastic agents.
PCT/IB1998/001046 1997-07-08 1998-07-08 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers Ceased WO1999002545A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
NZ501990A NZ501990A (en) 1997-07-08 1998-07-08 Compositions containing antigen-binding fragments that recognise the antigen recognised by a recombinant 4B5 antibody
EP98929569A EP1000082A2 (en) 1997-07-08 1998-07-08 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
JP2000502064A JP2001509369A (en) 1997-07-08 1998-07-08 Antigen binding fragments designated 4B5 that specifically detect cancer cells, nucleotides encoding the fragments, and their use for cancer prevention and detection
AU79273/98A AU7927398A (en) 1997-07-08 1998-07-08 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
CA002295375A CA2295375A1 (en) 1997-07-08 1998-07-08 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5194597P 1997-07-08 1997-07-08
US60/051,945 1997-07-08

Publications (2)

Publication Number Publication Date
WO1999002545A2 WO1999002545A2 (en) 1999-01-21
WO1999002545A3 true WO1999002545A3 (en) 1999-04-01

Family

ID=21974384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001046 Ceased WO1999002545A2 (en) 1997-07-08 1998-07-08 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers

Country Status (6)

Country Link
EP (1) EP1000082A2 (en)
JP (1) JP2001509369A (en)
AU (1) AU7927398A (en)
CA (1) CA2295375A1 (en)
NZ (1) NZ501990A (en)
WO (1) WO1999002545A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2184584C (en) 1994-03-08 2003-04-08 Jing-Shan Hu Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
EP1265918A1 (en) * 2000-03-15 2002-12-18 Incyte Genomics, Inc. Human immune response proteins
WO2002011769A1 (en) 2000-08-04 2002-02-14 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
DE10059930A1 (en) * 2000-11-23 2002-05-29 Fischer Peter Composition for treating tumors that produce disialoganglioside GD2, comprises human antibody fragment able to induce anti-idiotypic antibodies
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
EP2228389B1 (en) * 2001-04-13 2015-07-08 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US7473424B2 (en) * 2003-01-31 2009-01-06 The Scripps Research Institute Anti-dengue virus antibodies and compositions
TWI434855B (en) 2006-11-21 2014-04-21 Hoffmann La Roche Conjugate and its use as a standard in an immunoassay
CA2932480A1 (en) * 2013-12-16 2015-06-25 Texas Tech University System Anti-ron monoclonal antibodies as a cytotoxic drug delivery system for targeted cancer therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996020277A2 (en) * 1994-12-28 1996-07-04 University Of Kentucky Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen
WO1996022373A2 (en) * 1995-01-17 1996-07-25 University Of Kentucky Monoclonal antibody 1a7 and use for the treatment of melanoma and small cell carcinoma
US5653977A (en) * 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653977A (en) * 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen
WO1996020277A2 (en) * 1994-12-28 1996-07-04 University Of Kentucky Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen
WO1996022373A2 (en) * 1995-01-17 1996-07-25 University Of Kentucky Monoclonal antibody 1a7 and use for the treatment of melanoma and small cell carcinoma

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
G. SEN ET AL.: "An alternative strategy for inducing predominantly IgG antibodies and T cell responses against disialoganglioside GD2 using an anti-idiotype antibody.", THE FASEB JOURNAL, vol. 10, no. 6, 30 April 1996 (1996-04-30), Bethesda, MD, USA, pages A1059, XP002091382 *
H. ZEYTIN ET AL.: "DNA vaccine based on the structure of an anti-idiotype antibody mimicking the GD2 ganglioside.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 38, March 1997 (1997-03-01), USA, pages 399, XP002091383 *
M. SALEH ET AL.: "Generation of a human anti-idiotypic antibody that mimics the GD2 antigen.", THE JOURNAL OF IMMUNOLOGY, vol. 151, no. 6, 15 September 1993 (1993-09-15), Baltimore, MD, USA, pages 3390 - 3398, XP002091381 *
P. TRIPATHI ET AL.: "Anti-idiotype-cytokine fusion protein for breast cancer therapy.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 38, March 1997 (1997-03-01), USA, pages 84, XP002091384 *
R. SOMASUNDARAM ET AL.: "Anti-idiotypic antibodies functionally mimic GD2 gangliosides.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 38, March 1997 (1997-03-01), USA, pages 84, XP002091385 *

Also Published As

Publication number Publication date
NZ501990A (en) 2002-09-27
EP1000082A2 (en) 2000-05-17
WO1999002545A2 (en) 1999-01-21
JP2001509369A (en) 2001-07-24
CA2295375A1 (en) 1999-01-21
AU7927398A (en) 1999-02-08

Similar Documents

Publication Publication Date Title
WO1997044461A3 (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
WO1999002545A3 (en) Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
NO913211L (en) NEW MONOCLONAL ANTIBODY AGAINST NEW ANTIGEN ANNOUNCED TO HUMAN TUMORS.
DK2289A (en) MONOCLONAL ANTIBODIES AND THEIR PREPARATION AND USE
HUP0500345A2 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
MX9705349A (en) Monoclonal antibody 1a7 and use for the treatment of melanoma and small cell carcinoma.
NO331072B1 (en) Composition comprising an angiogenesis inhibitor and an anti-tumor immunotherapeutic agent as well as uses of the same.
EP0755409A1 (en) Monoclonal antibody to oncofetal protein for treating and detecting cancer
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
RU2008128244A (en) METHODS FOR IDENTIFICATION OF TUMORS SUSCEPTIBLE TO TREATMENT BY ANTIBODIES AGAINST ERBB2
RU94028282A (en) Biospecific antibody, method of its preparing, monoclonal antibodies, pharmaceutical preparation, pharmaceutical sets, method of tumor cell removal, use of biospecific antibody fragment
AU3125289A (en) Monoclonal antibodies directed against human tumor necrosis factor - receptor
WO2004060304A3 (en) Novel compositions and methods in cancer
WO1996022373A3 (en) Monoclonal antibody 1a7 and use for the treatment of melanoma and small cell carcinoma
WO2000055629A3 (en) Methods of diagnosing and treating breast cancer
CA2579523A1 (en) Atad3a-binding molecules for treatment, detection and prevention of cancer
SG66274A1 (en) Compositions and methods for treating small cell and nonsmall cell lung cancers
WO2004003155A3 (en) Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
WO2003080808A3 (en) Novel compositions and methods in cancer
WO1994011508A3 (en) Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
CA2255540A1 (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
WO1991017187A3 (en) A 35kd tumor associated protein antigen: uses and methods of detection
WO1999038500A3 (en) The human calcium-sensing receptor in the detection and treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 501990

Country of ref document: NZ

Ref document number: 79273/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2295375

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2295375

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998929569

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998929569

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998929569

Country of ref document: EP